I personally doubt the last reason. Because almost all GBM tumors will recur, the incidence can’t be low. 2. Measuring outcome in clinical trials Only OS is good. The text has an interesting idea, which is thatPFS is influenced only by the treatment received, while OS also reflects subse...
Figure 1 Treatment options for recurrent glioblastoma. Inclusion in a clinical trial is always the preferred option. Patients who benefit from S-S are those with a localized relapse in non-eloquent areas, in whom a complete or subtotal resection of the enhancing tumor can be performed...
Glioblastoma (GB) is the most common high-grade intracranial malignant tumor with highly malignant biological behavior and a high recurrence rate. Although anti-PD-1/PD-L1 antibodies have achieved significant survival benefits in several kinds of solid tumors, the phase III clinical trial Checkmate 1...
This led to the first in human trials of DNX-2401 for glioblastoma, where in addition to direct oncolytic effects, we showed that the delivery of the virus into tumors induced an immunogenic environment with increased T-cell infiltration and also altered the expression of checkpoint proteins10. ...
GlioblastomaPrognostic factorsRadiotherapyRecurrenceSurgeryBackground:The majority of patients with glioblastoma (GBM) experience disease progression. At recurrence, treatment options have limited efficacy. Many studies report a limited and short duration response rate. Although clinical trials represent the "...
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor and represents one of the toughest therapeutic challenges in oncology. On recurrence after radiation therapy and temozolomide, median survival historically has ranged from 4 to 7 months.1'2 Interest in antiangiogenic approach...
Pathway inhibition, via multisite kinase inhibitors or a carefully selected combination of molecular drugs with or without cytotoxic agents, is currently undergoing evaluation in clinical trials and may improve outcomes in these patients. 展开 关键词: bevacizumab EGFR glioblastoma molecular targeted ...
ClinicalTrials数据库提供临床试验Tris-CAR-T Cell Therapy for Recurrent Glioblastoma的登记号NCT05577091,试验分期Phase 1以及申办者Beijing Tiantan Hospital的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
ClinicalTrials数据库提供临床试验Surgery for Recurrent Glioblastoma的登记号NCT02394626,试验分期Phase 2以及申办者Insel Gruppe AG, University Hospital Bern的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
TTFields were successfully tested in patients with newly diagnosed glioblastoma, leading to a significant prolongation of overall survival (OS) when given in combination with maintenance temozolomide [18]. The anti-mitotic effects of TTFields have been shown in multiple tumor models [17,23]. In ...